Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for GenMont Biotech's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, GenMont Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a Buyback Yield % of 0.74 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on GenMont Biotech and its competitors. According to the industry distribution chart, GenMont Biotech ranks #59 out of 740 companies in the Biotechnology industry, placing it in the top 8%.
Is GenMont Biotech's Buyback Yield % too high?
GenMont Biotech's current Buyback Yield % is 0.74. Based on the distribution chart, GenMont Biotech ranks #59 out of 740 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenMont Biotech has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #59 out of 740 companies for Buyback Yield %. This places GenMont Biotech in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on GenMont Biotech and its competitors. GenMont Biotech's current Buyback Yield % is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.26, compared to a current price of NT$16.30 — trading 37.9% below its estimated fair value. The current Buyback Yield % is 0.74. GenMont Biotech's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current Buyback Yield % is 0.74 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.30 is trading 37.9% below its estimated GF Value™ of NT$26.26.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
Buyback Yield %: 0.74
GF Value™: NT$26.26 vs. price of NT$16.30 (37.9% below fair value)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
83GF Score
Get the complete analysis for TPE:3164
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
